Cellebrite DI (NASDAQ:CLBT) Stock: Insider Marcus Jewell Sells 12,462 Shares

Cellebrite DI logo with Technology background
Image from MarketBeat Media, LLC.

Key Points

  • Cellebrite CRO Marcus Jewell sold 12,462 shares at an average price of $11.55, for about $143,936. The trade was made under a pre-arranged Rule 10b5-1 plan; afterward, he held 414,273 shares.
  • Shares opened at $10.65, within a 52-week range of $9.58–$19.39. Analysts’ consensus rating was “Moderate Buy,” with an average price target of $14.75.
  • Interested in Cellebrite DI? Here are five stocks we like better.

Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report) CRO Marcus Jewell sold 12,462 shares of the business's stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $11.55, for a total transaction of $143,936.10. Following the sale, the executive owned 414,273 shares of the company's stock, valued at $4,784,853.15. This represents a 2.92% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Marcus Jewell also recently made the following trade(s):

  • On Tuesday, November 17th, Marcus Jewell sold 9,928 shares of Cellebrite DI stock. The stock was sold at an average price of $10.66, for a total value of $105,832.48.
  • On Thursday, November 12th, Marcus Jewell sold 393 shares of Cellebrite DI stock. The shares were sold at an average price of $13.31, for a total value of $5,230.83.
  • On Friday, August 21st, Marcus Jewell sold 12,562 shares of Cellebrite DI stock. The stock was sold at an average price of $11.24, for a total transaction of $141,196.88.

Cellebrite DI Stock Performance

Shares of Cellebrite DI stock opened at $10.65 on Wednesday. Cellebrite DI Ltd. has a 1 year low of $9.58 and a 1 year high of $19.39. The company's fifty day moving average is $11.58 and its two-hundred day moving average is $13.17. The company has a market capitalization of $2.66 billion, a P/E ratio of 33.70, a PEG ratio of 1.41 and a beta of 1.06.

Institutional Trading of Cellebrite DI

Large investors have recently bought and sold shares of the company. PNC Financial Services Group Inc. lifted its holdings in Cellebrite DI by 59.6% in the first quarter. PNC Financial Services Group Inc. now owns 7,456 shares of the company's stock worth $103,000 after purchasing an additional 2,785 shares during the period. Elevation Wealth Partners LLC lifted its position in shares of Cellebrite DI by 93.3% during the 3rd quarter. Elevation Wealth Partners LLC now owns 5,833 shares of the company's stock valued at $66,000 after acquiring an additional 2,816 shares during the last quarter. Pacer Advisors Inc. boosted its position in shares of Cellebrite DI by 91.1% in the 1st quarter. Pacer Advisors Inc. now owns 7,607 shares of the company's stock valued at $105,000 after purchasing an additional 3,626 shares during the period. Moody National Bank Trust Division boosted its holdings in shares of Cellebrite DI by 7.6% in the second quarter. Moody National Bank Trust Division now owns 60,691 shares of the company's stock worth $886,000 after buying an additional 4,284 shares during the period. Finally, Quantinno Capital Management LP purchased a new position in Cellebrite DI during the 1st quarter worth approximately $150,000. Institutional investors and hedge funds own 45.88% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. JPMorgan Chase & Co. reduced their target price on shares of Cellebrite DI from $16.00 to $15.00 and set an "overweight" rating for the company in a research note on Friday, November 13th. Needham & Company LLC upped their target price on Cellebrite DI from $12.50 to $14.00 and gave the company a "buy" rating in a report on Thursday, November 12th. Lake Street Capital dropped their price objective on shares of Cellebrite DI from $21.00 to $15.00 and set a "buy" rating for the company in a research note on Friday, August 14th. DA Davidson reissued a "buy" rating and issued a $15.00 target price on shares of Cellebrite DI in a research note on Tuesday, September 15th. Finally, Weiss Ratings raised Cellebrite DI from a "sell (d)" rating to a "sell (d+)" rating in a research note on Friday. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Cellebrite DI currently has an average rating of "Moderate Buy" and a consensus price target of $14.75.

View Our Latest Report on CLBT

About Cellebrite DI

(Get Free Report)

Cellebrite DI Ltd. develops digital intelligence software and services that help organizations access, collect, preserve and analyze digital evidence. Its tools are used to investigate information from mobile devices, computers, cloud sources and other digital systems. The company's offerings include its UFED platform for extracting data from digital devices, Physical Analyzer for examining and interpreting evidence, and analytics and case-management tools such as Pathfinder and Guardian. Customers include law enforcement, public safety, intelligence and defense agencies, as well as organizations in the private sector.

Featured Articles

Insider Buying and Selling by Quarter for Cellebrite DI (NASDAQ:CLBT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Cellebrite DI Right Now?

Before you consider Cellebrite DI, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.

While Cellebrite DI currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines